

Freiburg Medical Laboratory ME LLC, P.O.Box 3068, Dubai

Tel: 04 396 2227

Fax: 04 396 2228



Amisulpride

General:

Amisulpride is a neuroleptic drug which was approved for the treatment of acute and chronic schizophrenia. It is a benzamide and its structure is similar to sulpiride and remoxipride. Both drugs are used as neuroleptic and antidepressant drugs. At a low dosage (100 mg per day) amisulpride positively influences emotional and social retreats. It probably blocks primary presynaptic D2/D3-receptors. This increases dopamine which shows disinhibiting effects and is probably responsible for the improvement of the negative symptomatology. Doses from 400 to 800 mg per day are used to influence delusions, hallucinations, thinking disorders, hostility and distrust. It blocks the postsynaptic D2/D3-receptors in the limbic system. Apparently D2-receptors are blocked less strongly in the striatum than with other neuroleptics, which leads to lower extrapyramidal motor side effects.

Indication: Therapy monitoring

Material: 1 ml of serum

TAT: 7-10 days*

Method: LCMS

Units: µg/l

Ref.-range: 100-320

For complete list of laboratory test offered at Freiburg Medical Laboratory, please visit http://www.fml-dubai.com/parameter-listings/

Page 1 of 1 Updated 24/03/2022

